Abstract Views :438 |
PDF Views:0
Authors
Affiliations
1 Lecturer, Faculty of Medicine and Health Sciences, Warmadewa University, Jl. Terompong No. 24 Denpasar, Bali, ID
2 Lecturer, Tabanan General Hospital, Jl. Pahlawan no 14, Tabanan, ID
3 Lecturer, Sanjiwani General Hospital.
Jl. CiungWenara No 2 Gianyar, Bali, ID
4 Lecturer, Faculty of Medicine, Public Health, and Nursing, Gadjah Mada University, Jl. Farmako, Sekip Utara, Yogyakarta, ID
Source
Indian Journal of Public Health Research & Development, Vol 11, No 2 (2020), Pagination: 1456-1461
Abstract
Background and Aim: Diabetic nephropathy is a complication of diabetes mellitus which can lead to kidney failure. Monocyte Chemoattractant Protein-1 (MCP-1) is a protein that is expected to be a biomarker of diabetic nephropathy. The purpose of this study was to examined the relationship of MCP-1 with diabetic nephropathy in Indonesia, especially in Bali therefore the accuracy in detecting diabetic nephropathy can be assessed. Method: One hundred and sixteen patients with type 2 diabetes mellitus with diabetic nephropathy (n = 37) and without diabetic nephropathy (n = 79) were included in this study. MCP-1 serum was examined using the enzyme-linked immunosorbent assay (ELISA) method. Result: MCP-1 serum levels were significantly higher in patients with diabetic nephropathy (p <0.001). Analysis of receiver operating characteristic (ROC) curve for diabetic nephropathy detection showed that cut-off point of MCP-1 serum was 436 pg/ml with a sensitivity of 83.7% and 84.8% specificity. Conclusion: It can be concluded that MCP-1serum can be considered as a biomarker for detection of diabetic nephropathy.
Keywords
MCP-1 serum, diabetic nephropathy, biomarker
